BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 20406615)

  • 1. High incidence rate of vertebral fractures during chronic prednisone treatment, in spite of bisphosphonate or alfacalcidol use. Extension of the alendronate or alfacalcidol in glucocorticoid-induced osteoporosis-trial.
    Hoes JN; Jacobs JW; Hulsmans HM; De Nijs RN; Lems WF; Bruyn GA; Geusens PP; Bijlsma JW
    Clin Exp Rheumatol; 2010; 28(3):354-9. PubMed ID: 20406615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis.
    de Nijs RN; Jacobs JW; Lems WF; Laan RF; Algra A; Huisman AM; Buskens E; de Laet CE; Oostveen AC; Geusens PP; Bruyn GA; Dijkmans BA; Bijlsma JW;
    N Engl J Med; 2006 Aug; 355(7):675-84. PubMed ID: 16914703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture: the Japanese Osteoporosis Intervention Trial (JOINT) - 02.
    Orimo H; Nakamura T; Fukunaga M; Ohta H; Hosoi T; Uemura Y; Kuroda T; Miyakawa N; Ohashi Y; Shiraki M;
    Curr Med Res Opin; 2011 Jun; 27(6):1273-84. PubMed ID: 21554143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of bone metabolism during early stage and clinical benefits of early intervention with alendronate in patients with systemic rheumatic diseases treated with high-dose glucocorticoid: Early DIagnosis and Treatment of OsteopoRosis in Japan (EDITOR-J) study.
    Tanaka Y; Mori H; Aoki T; Atsumi T; Kawahito Y; Nakayama H; Tohma S; Yamanishi Y; Hasegawa H; Tanimura K; Negoro N; Ueki Y; Kawakami A; Eguchi K; Saito K; Okada Y
    J Bone Miner Metab; 2016 Nov; 34(6):646-654. PubMed ID: 26308708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alendronate protects premenopausal women from bone loss and fracture associated with high-dose glucocorticoid therapy.
    Okada Y; Nawata M; Nakayamada S; Saito K; Tanaka Y
    J Rheumatol; 2008 Nov; 35(11):2249-54. PubMed ID: 19031508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of alendronate on glucocorticoid-induced osteoporosis in Japanese women with systemic autoimmune diseases: versus alfacalcidol.
    Takeda S; Kaneoka H; Saito T
    Mod Rheumatol; 2008; 18(3):271-6. PubMed ID: 18427724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical trial: comparison of alendronate and alfacalcidol in glucocorticoid-associated osteoporosis in patients with ulcerative colitis.
    Kitazaki S; Mitsuyama K; Masuda J; Harada K; Yamasaki H; Kuwaki K; Takedatsu H; Sugiyama G; Tsuruta O; Sata M
    Aliment Pharmacol Ther; 2009 Feb; 29(4):424-30. PubMed ID: 19035979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient satisfaction and efficacy of switching from weekly bisphosphonates to monthly minodronate for treatment and prevention of glucocorticoid-induced osteoporosis in Japanese patients with systemic rheumatic diseases: a randomized, clinical trial.
    Tamechika SY; Sasaki K; Hayami Y; Ohmura SI; Maeda S; Iwagaitsu S; Naniwa T
    Arch Osteoporos; 2018 Jun; 13(1):67. PubMed ID: 29904824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study.
    Kushida K; Shiraki M; Nakamura T; Kishimoto H; Morii H; Yamamoto K; Kaneda K; Fukunaga M; Inoue T; Nakashima M; Orimo H
    J Bone Miner Metab; 2004; 22(5):462-8. PubMed ID: 15316867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Alendronate more effective than alfacalcidol in the prevention of osteoporosis in patients with rheumatic disease who are starting glucocorticoid therapy].
    de Nijs RN; Jacobs JW; Lems WF; Laan RF; Algra A; Huisman AM; Buskens E; de Laet CE; Oostveen JC; Geusens PP; Bruyn GA; Dijkmans BA; Bijlsmat JW
    Ned Tijdschr Geneeskd; 2007 May; 151(21):1178-85. PubMed ID: 17557758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cost effectiveness analysis of calcium and vitamin D supplementation, etidronate, and alendronate in the prevention of vertebral fractures in women treated with glucocorticoids.
    Buckley LM; Hillner BE
    J Rheumatol; 2003 Jan; 30(1):132-8. PubMed ID: 12508402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alfacalcidol versus plain vitamin D in the treatment of glucocorticoid/inflammation-induced osteoporosis.
    Ringe JD; Faber H; Fahramand P; Schacht E
    J Rheumatol Suppl; 2005 Sep; 76():33-40. PubMed ID: 16142849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.
    Saag KG; Zanchetta JR; Devogelaer JP; Adler RA; Eastell R; See K; Krege JH; Krohn K; Warner MR
    Arthritis Rheum; 2009 Nov; 60(11):3346-55. PubMed ID: 19877063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential of alfacalcidol for reducing increased risk of falls and fractures.
    Ringe JD; Schacht E
    Rheumatol Int; 2009 Aug; 29(10):1177-85. PubMed ID: 19159932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Importance of alfacalcidol in clinical conditions characterized by high rate of bone loss.
    Reginster JY; Lecart MP; Richy F
    J Rheumatol Suppl; 2005 Sep; 76():21-5. PubMed ID: 16142847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.
    Saag KG; Emkey R; Schnitzer TJ; Brown JP; Hawkins F; Goemaere S; Thamsborg G; Liberman UA; Delmas PD; Malice MP; Czachur M; Daifotis AG
    N Engl J Med; 1998 Jul; 339(5):292-9. PubMed ID: 9682041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early use of alendronate as a protective factor against the development of glucocorticoid-induced bone loss in childhood-onset rheumatic diseases: a cross-sectional study.
    Inoue Y; Mitsunaga K; Yamamoto T; Chiba K; Yamaide F; Nakano T; Morita Y; Yamaide A; Suzuki S; Arima T; Yamaguchi KI; Tomiita M; Shimojo N; Kohno Y
    Pediatr Rheumatol Online J; 2018 Jun; 16(1):36. PubMed ID: 29914510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis.
    Ringe JD; Dorst A; Faber H; Schacht E; Rahlfs VW
    Rheumatol Int; 2004 Mar; 24(2):63-70. PubMed ID: 14513268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incident Vertebral Fractures and Risk Factors in the First Three Years Following Glucocorticoid Initiation Among Pediatric Patients With Rheumatic Disorders.
    LeBlanc CM; Ma J; Taljaard M; Roth J; Scuccimarri R; Miettunen P; Lang B; Huber AM; Houghton K; Jaremko JL; Ho J; Shenouda N; Matzinger MA; Lentle B; Stein R; Sbrocchi AM; Oen K; Rodd C; Jurencak R; Cummings EA; Couch R; Cabral DA; Atkinson S; Alos N; Rauch F; Siminoski K; Ward LM;
    J Bone Miner Res; 2015 Sep; 30(9):1667-75. PubMed ID: 25801315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Combination of alendronate plus alfacalcidol in the treatment of osteoporosis. Rationale, preclinical data and clinical evidence].
    Von Schacht E; Dambacher MA; Ringe JD; Dukas L
    MMW Fortschr Med; 2012 Apr; 154 Suppl 1():10-21. PubMed ID: 23427364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.